A committee of the European Medicines Agency (EMA) has recommended the approval of Ipsen‘s tovorafenib for the treatment of pediatric low-grade glioma (pLGG).

A low dose of alnodesertib added to standard chemotherapy significantly reduced the likelihood of disease progression among people with platinum-resistant high-grade serous ovarian carcinoma (HGSOC)…

March is Myeloma Action Month (MAM), and organizations around the world are participating to support patients, families, and caregivers who live with myeloma. This year,…